Aquestive Therapeutics AQST
$3.46 −$0.25 (-6.61%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.52 +1.73%
Open$3.62
Prev close$3.71
Day range$3.41 – $3.65
Volume3.36M
Market cap$434.88M
P/E (TTM)–
Dividend yield–
AQST Stock News
Headlines matching Aquestive Therapeutics or the AQST ticker, most recent first.
- H.C. Wainwright Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10
- Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $6
- LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10
- LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Raises Target Price to $10 Positive
- Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Aquestive Therapeutics (AQST) and Alto Neuroscience, Inc. (ANRO)
- LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
- Cantor Fitzgerald Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $11
- Oppenheimer Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $8
- A Quick Look at Today's Ratings for Aquestive Therapeutics(AQST.US), With a Forecast Between $6 to $9
- A. G. P. Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
- Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Ardent Health Partners, Inc. (ARDT)
- Piper Sandler Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $8
- Oppenheimer Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Announces Target Price $8
- A. G. P. Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Cuts Target Price to $9 Negative
- Leerink Partners Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Announces Target Price $9
No comments yet — be the first to weigh in on AQST.
Sign in to join the discussion.